Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
14.58 USD | +5.58% | +14.80% | -33.06% |
Business Summary
Number of employees: 94
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Monoclonal Antibody
100.0
%
| 2 | 100.0 % | 0 | 100.0 % | -82.28% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 2 | 100.0 % | 0 | 100.0 % | -82.28% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Stephen Mahoney
CEO | Chief Executive Officer | 53 | 30/23/30 |
Seth Harmon
DFI | Director of Finance/CFO | 45 | 01/23/01 |
Thomas Ciulla
CTO | Chief Tech/Sci/R&D Officer | 59 | 01/23/01 |
Thomas Beetham
COO | Chief Operating Officer | 55 | 30/23/30 |
Angela Sheen
CTO | Chief Tech/Sci/R&D Officer | - | 01/20/01 |
Shan Wu
PRN | Corporate Officer/Principal | - | 30/23/30 |
Vahe Bedian
PRN | Corporate Officer/Principal | - | 28/20/28 |
Anthony Casciano
PRN | Corporate Officer/Principal | - | - |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Arlene Morris
BRD | Director/Board Member | 72 | 03/18/03 |
Tomas Kiselak
CHM | Chairman | 38 | 28/20/28 |
Stephen Mahoney
CEO | Chief Executive Officer | 53 | 30/23/30 |
Peter Harwin
BRD | Director/Board Member | 38 | 28/20/28 |
Jennifer Moses
BRD | Director/Board Member | 49 | 14/21/14 |
Sarah Gheuens
BRD | Director/Board Member | 45 | 25/23/25 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 0 | 172,435 | 0 | 0 | 92.69 % |
Stock B | 0 | 143,522 | 0 | 0 | |
Stock C | 1 | 63,822,468 | 59,159,235 ( 92.69 %) | 0 |
Company contact information
Viridian Therapeutics, Inc.
221 Crescent Street Suite 401
02453, Waltham
+
http://www.viridiantherapeutics.comSector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-33.06% | 931M | |
+26.28% | 48.09B | |
-3.99% | 40.43B | |
+45.32% | 40.62B | |
-6.20% | 28.36B | |
+6.36% | 24.89B | |
-21.47% | 19.01B | |
+27.58% | 12.09B | |
-2.75% | 11.8B | |
-2.02% | 11.88B |
- Stock Market
- Equities
- VRDN Stock
- Company Viridian Therapeutics, Inc.